Overview

A Clinical Trial to Evaluate the Efficacy and Safety of Elvitegravir / Cobicistat / Emtricitabine / Tenofovir Alafenamide as a First-line Treatment in Naïve Patients With HIV-1 Infection With Severe Immunosuppression

Status:
Completed

Trial end date:
2020-05-28

Target enrollment:

Participant gender:

Summary

Phase IV, open, multicentre and single-arm study. 50 HIV infection naive patients with severe immunosuppression will be recruited to evaluate the efficacy and safety of elvitegravir / cobicistat / emtricitabine / tenofovir alafenamide as a first-line treatment.

Phase:

Phase 4

Details

Lead Sponsor:

Fundacion SEIMC-GESIDA

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

Cobicistat
Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
Emtricitabine
Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
Genvoya
Tenofovir